Atm selectively regulates distinct p53-dependent cell-cycle checkpoint and apoptotic pathways

Nature Genetics

Volumn 17, Issue 4, 1997, Pages 453-456

  Barlow, Carrolee ^a   Brown, Kevin D ^b   Deng, Chu Xia ^a   Tagle, Danilo A ^b   Wynshaw Boris, Anthony ^a  

^a NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^b NATIONAL HUMAN GENOME RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; PROTEIN BAX; PROTEIN P21; PROTEIN P53;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; ATAXIA TELANGIECTASIA; CELL CYCLE; CONTROLLED STUDY; DNA DAMAGE; IONIZING RADIATION; MOUSE; MUTANT; NONHUMAN; PRIORITY JOURNAL; THYMUS;

ANIMALIA; ATAXIA; ATAXIA TELANGIECTASIA;

EID: 0030667522     PISSN: 10614036     EISSN: None     Source Type: Journal    
DOI: 10.1038/ng1297-453     Document Type: Article

References (31)

1. Kastan, M.B. et al. A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia. Cell 71, 587-597 (1992).
2. Lu, X. & Lane, D.P. Differential induction of transcriptionally active p53 following UV or ionizing radiation: defects in chromosome instability syndromes? Cell 75, 765-778 (1993).
3. Khanna, K.K. & Lavin, M.F. Ionizing radiation and UV induction of p53 protein by different pathways in ataxia-telangiectasia cells. Oncogene 8, 3307-3312 (1993).
4. Xu, Y. & Baltimore, D. Dual responses of ATM in the cellular response to irradiation and in cell growth. Genes Dev. 10, 2401-2410 (1996).
5. Baskaran, R. et al. Ataxia telangiectasia mutant protein activates c-Abl tyrosine kinase in response to ionizing radiation. Nature 387, 516-519 (1997).
6. Ko, L.J. & Prives, C. p53: puzzle and paradigm. Genes Dev. 10, 1054-1072 (1996).
7. Levine, A.J. p53, the cellular gatekeeper for growth and division. Cell 88, 323-331 (1997).
8. Jacks, T. et al. Tumor spectrum analysis in p53-mutant mice. Curr. Biol. 4, 1-7 (1994).
9. CIP1/WAF1 undergo normal development, but are defective in G1 checkpoint control. Cell 82, 675-684 (1995).
10. Shiloh, Y. Ataxia-telangiectasia: closer to unraveling the mystery. Eur. J. Hum. Genet. 3, 116-38 (1995).
11. Meyn, M.S. Ataxia-telangiectasia and cellular responses to DNA damage. Cancer Res. 55, 5991-6001 (1995).
12. Barlow, C. et al. Atm-deficient mice: a paradigm of ataxia telangiectasia. Cell 86, 159-171 (1996).
13. Meyn, M.S., Strasfeld, L. & Allen, C. Testing the role of p53 in the expression of genetic instability and apoptosis in ataxia-telangiectasia. Int. J. Radiat. Biol. 66, S141-S149 (1994).
14. Westphal, C.H. et al. atm and p53 cooperate in apoptosis and suppression of tumorigenesis, but not in resistance to acute radiation toxicity. Nature Genet. 16, 397-401 (1997).
15. Kastan, M.B., Onyekwere, O., Sidransky, D., Vogelstein, B. & Craig, R.W. Participation of p53 protein in the cellular response to DNA damage. Cancer Res. 51, 6304-6311 (1991).
16. Brugarolas, J. et al. Radiation-induced cell cycle arrest compromised by p21 deficiency. Nature 377, 552-557 (1995).
17. Lowe, S.W., Schmitt, E.M., Smith, S.W., Osborne, B.A. & Jacks, T. pS3 is required for radidtion-indiced apaptosis in mouse thymocytes. Nature 362, 847-849 (1993).
18. Clarke, A.R. et al. Thymocyte apoptosis induced by p53-dependent and independent pathways. Nature 362, 849-852 (1993).
19. Santana, P. et al. Acid sphingomyelinase-deficient human lymphoblasts and mice are defective in radiation-induced apoptosis. Cell 86, 189-199 (1996).
20. Chen, G. & Lee, E.Y.H.-P. The product of the ATM gene is a 370-kDa nuclear phosphoprotein. J. Biol. Chem. 271, 33693-33697 (1996).
21. Lakin, N.D. et al. Analysis of the ATM protein in wild-type and ataxia telangiectasia cells. Oncogene 13, 2707-2716 (1996).
22. Brown, K.D. et al. The ataxia-telangiectasia gene product, a constitutively expressed nuclear protein that is not upregulated following genome damage. Proc. Natl. Acad. Sci. USA 94, 1840-1845 (1997).
23. El-Deiry, W.S. et al. WAF1, a potential mediator of p53 tumor suppression. Cell 75, 817-825 (1993).
24. Harper, J.W., Adami, G.R., Wei, N., Keyomarsi, K. & Elledge, S.J. The p21 cdk-interacting protein Cip1 is a potent inhibitor of G1-cyclin-dependent kinases. Cell 75, 805-816 (1993).
25. Miyashita, T. & Reed, J.C. Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell 80, 293-299 (1995).
26. Friedlander, P., Haupt, Y., Prives, C. & Oren, M. A mutant p53 that discriminates between p53-responsive genes and cannot induce apoptosis. Mol. Cell. Biol. 16, 4961-4971 (1996).
27. Chen, X., Ko, L.J., Jayaraman, L. & Prives, C. p53 levels, functional domains, and DNA damage determine the extent of the apoptotic response of tumor cells. Genes Dev. 10, 2438-2451 (1996).
28. Pietenpol, J.A. et al. Sequence-specific transcriptional activation is essential for growth suppression by p53. Proc. Natl. Acad. Sci. USA 91, 1998-2002 (1994).
29. White, R.A., Terry, N.H., Meistrich, M.L. & Calkins, D.P. Improved method for computing potential doubling time from flow cytometric data. Cytometry 11, 314-317 (1990).
30. Luna, L.G. Histopathological Methods and Color Atlas of Special Stains and Tissue (American Histolabs, Gaithersburg, Maryland, 1992).
31. Harlow, E. & Lane, D. Antibodies: A Laboratory Manual (Cold Spring Harbor Laboratory, Cold Spring Harbor, New York, 1988).